pharmaphorum2d
FDA says no to AZ's Fasenra for nasal polyp indication
Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab) was approved to treat CRSwNP in 2019, and was joined on the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.
Zacks Investment Research on MSN2d
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
Investing19d
GSK's depemokimab accepted by FDA for asthma, CRSwNP indications
CRSwNP affects 2.1% of the US population ... bringing expertise in immunology and infectious diseases to the Board. Lastly, GSK's Nucala treatment for COPD is under review by China's National ...
FierceBiotech20d
GSK gears up for depemokimab debut with twin FDA filings and phase 3 data dump
CRSwNP is an inflammatory disease that obstructs ... Novartis’ Xolair and GSK’s own Nucala.
Investing19d
GSK’s depemokimab accepted by FDA for asthma, CRSwNP indications
CRSwNP affects 2.1% of the US population ... bringing expertise in immunology and infectious diseases to the Board. Lastly, GSK’s Nucala treatment for COPD is under review by China’s National Medical ...
pharmaphorum2d
GSK asthma hope depemokimab works in second indication
Nucala is approved for four indications, namely severe eosinophilic asthma CRSwNP, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES), and has also shown ...